Philip Morris International has clawed back 1.2% on the week to close at $180.91, reversing much of the weakness flagged in last week's note — but options positioning suggests investors are not yet ready to drop their guard ahead of the July 22 Q2 print.
The options market tells the more interesting story this week. Puts continue to dominate call volumes at a ratio of 1.13, almost exactly in line with PM's elevated 20-day average of 1.13 and near the 52-week high of 1.16. The z-score of just 0.22 signals the skew hasn't worsened, but the baseline itself is defensive — PM's floor-level PCR is well above where most large-cap consumer staples trade. That persistent put-heaviness reflects how the market has been running into each recent earnings event: cautious, with hedges in place rather than outright short bets.
Short interest is genuinely low and the borrow market is extraordinarily loose, making it a poor vehicle for bearish expression. SI stands at 1.1% of free float — essentially unchanged on the week after a brief mid-week spike to 1.23% that quickly faded. Borrow costs are running at just 0.43%, down roughly 16% on the week from a modest intramonth peak. Availability is effectively unlimited at over 9,600%, the highest level in the 30-day window, meaning the lending pool has more than 95 shares available for every one currently borrowed. Shorts are not rebuilding after the April earnings pop, and the borrow market offers no squeeze angle whatsoever.
The Street remains broadly bullish, though not without nuance. Morgan Stanley raised its target to $200 on June 3 while keeping its Overweight rating — the most recent bellwether move on the name. That target now sits 10.5% above Tuesday's close of $180.91, consistent with the consensus mean of around $194. Bulls point to IQOS and Zyn volume momentum and the Swedish Match portfolio as the structural growth drivers for 2026 and beyond. Bears counter that the organic revenue growth corridor of 5-7% trails prior targets, combustible volumes keep declining, and Japan's impending IQOS excise increase adds a near-term pricing headwind. The EV/EBITDA at 16.4x has compressed modestly over the past 30 days, and the forward PE at 20.4x has eased by roughly 1.4 turns over the same period — a mild re-rating that brings PM closer to fair value against its own history. The dividend score ranks in the 97th percentile, still the most compelling single factor for the income-oriented investor base.
The earnings history sharpens the focus. The last Q2-equivalent print in April 2026 produced a 10.4% single-day gain and a 6.2% five-day follow-through — a notably strong reaction that the current subdued options positioning does not fully price for a repeat. The May event was quieter at under 1% on the day, though the five-day move reached nearly 11%. PM's post-earnings behaviour has been asymmetric: the big moves have been to the upside, and bears have not been rewarded by sitting in puts through the prints. The question heading into July 22 is whether IQOS and Zyn volume data confirm the re-acceleration story or hand ammunition to the bears via another combustible volume miss.
Among peers, MO gained just 0.5% on the week and BATS added 2.0%, while TPB outpaced the group with nearly 5.8% — the tobacco complex broadly drifted higher. PM's modest 1.2% week aligns it with the sector's cautious drift rather than any idiosyncratic re-rating. With the ORTEX short score easing slightly to 32.2 from 33.3 last week, the data picture is one of gently receding short pressure rather than any build — positioning looks comfortably long-biased rather than conflicted, and the next meaningful test arrives July 22.
See the live data behind this article on ORTEX.
Open PM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
